RECORD
Revolutionizing Personalized Cancer Vaccines with NEO: Novel Epitope Optimization Using an Aggregated Feed Forward and Recurrent Neural Network with LSTM Architecture
Machine Learning · Submitted 31 Oct 2024
abstract compiled · 2026-09-23 · no language-model review
The authors' main claim Using this model, personalized cancer vaccines can be produced with improved results (AUC = 0.9166, recall = 91.67 percent).
The compiled record
The paper's own sentences, arranged. Each label is drawn from a closed vocabulary; the number beside it is the probability the classifier gave that label. Numbers in the tables are the authors', checked by code. No sentence in this record was written by a model.
Open the compiled record
The abstract, sentence by sentence
As cancer cases continue to rise, with a 2023 study from Zhejiang and Harvard predicting a 31 percent increase in cases and a 21 percent increase in deaths by 2030, the need to find more effective treatments for cancer is greater than ever before. Traditional approaches to treating cancer, such as chemotherapy, often kill healthy cells because of their lack of targetability. In contrast, personalized cancer vaccines can utilize neoepitopes - distinctive peptides on cancer cells that are often missed by the body's immune system - that have strong binding affinities to a patient's MHC to provide a more targeted treatment approach. The selection of optimal neoepitopes that elicit an immune response is a time-consuming and costly process due to the required inputs of modern predictive methods. This project aims to facilitate faster, cheaper, and more accurate neoepitope binding predictions using Feed Forward Neural Networks (FFNN) and Recurrent Neural Networks (RNN). To address this, NEO was created. NEO requires next-generation sequencing data and uses a stacking ensemble method by calculating scores from state-of-the-art models (MHCFlurry 1.6, NetMHCstabpan 1.0, and IEDB). The model's architecture includes an FFNN and an RNN with LSTM layers capable of analyzing both sequential and non-sequential data. The results from both models are aggregated to produce predictions. Using this model, personalized cancer vaccines can be produced with improved results (AUC = 0.9166, recall = 91.67 percent).
background contribution method result interpretation main claim
| # | sentence | role | the authors' own work | states the main conclusion | strength |
|---|---|---|---|---|---|
| s0 | As cancer cases continue to rise, with a 2023 study from Zhejiang and Harvard predicting a 31 percent increase in cases and a 21 percent increase in deaths by 2030, the need to find more effective treatments for cancer is greater than ever before. | background 1.00 | 0.03 | 0.02 | asserted 0.90 |
| s1 | Traditional approaches to treating cancer, such as chemotherapy, often kill healthy cells because of their lack of targetability. | background 1.00 | 0.04 | 0.02 | asserted 0.93 |
| s2 | In contrast, personalized cancer vaccines can utilize neoepitopes - distinctive peptides on cancer cells that are often missed by the body's immune system - that have strong binding affinities to a patient's MHC to provide a more targeted treatment approach. | background 1.00 | 0.05 | 0.04 | asserted 0.94 |
| s3 | The selection of optimal neoepitopes that elicit an immune response is a time-consuming and costly process due to the required inputs of modern predictive methods. | background 0.52 | 0.07 | 0.02 | asserted 1.00 |
| s4 | This project aims to facilitate faster, cheaper, and more accurate neoepitope binding predictions using Feed Forward Neural Networks (FFNN) and Recurrent Neural Networks (RNN). | contribution 0.92 | 0.37 | 0.07 | asserted 0.84 |
| s5 | To address this, NEO was created. | contribution 0.96 | 0.79 | 0.03 | asserted 0.98 |
| s6 | NEO requires next-generation sequencing data and uses a stacking ensemble method by calculating scores from state-of-the-art models (MHCFlurry 1.6, NetMHCstabpan 1.0, and IEDB). | method 0.99 | 0.74 | 0.04 | asserted 1.00 |
| s7 | The model's architecture includes an FFNN and an RNN with LSTM layers capable of analyzing both sequential and non-sequential data. | method 1.00 | 0.74 | 0.04 | asserted 1.00 |
| s8 | The results from both models are aggregated to produce predictions. | method 1.00 | 0.76 | 0.08 | asserted 1.00 |
| s9 | Using this model, personalized cancer vaccines can be produced with improved results (AUC = 0.9166, recall = 91.67 percent). | result 1.00 | 0.87 | 0.76 | asserted 0.92 |
What was examined, and what was not
- arXiv listing abstract v1
- full text
- figures and tables
- references and citing sentences
- relations to other papers
- P abstract
- S sections
- T body sentences
- C citations
- R cross-paper relations
The paper
Original abstract
As cancer cases continue to rise, with a 2023 study from Zhejiang and Harvard predicting a 31 percent increase in cases and a 21 percent increase in deaths by 2030, the need to find more effective treatments for cancer is greater than ever before. Traditional approaches to treating cancer, such as chemotherapy, often kill healthy cells because of their lack of targetability. In contrast, personalized cancer vaccines can utilize neoepitopes - distinctive peptides on cancer cells that are often missed by the body's immune system - that have strong binding affinities to a patient's MHC to provide a more targeted treatment approach. The selection of optimal neoepitopes that elicit an immune response is a time-consuming and costly process due to the required inputs of modern predictive methods. This project aims to facilitate faster, cheaper, and more accurate neoepitope binding predictions using Feed Forward Neural Networks (FFNN) and Recurrent Neural Networks (RNN). To address this, NEO was created. NEO requires next-generation sequencing data and uses a stacking ensemble method by calculating scores from state-of-the-art models (MHCFlurry 1.6, NetMHCstabpan 1.0, and IEDB). The model's architecture includes an FFNN and an RNN with LSTM layers capable of analyzing both sequential and non-sequential data. The results from both models are aggregated to produce predictions. Using this model, personalized cancer vaccines can be produced with improved results (AUC = 0.9166, recall = 91.67 percent).
Human review
Discussion
Know something about this paper? Leave a comment, or highlight any passage above to comment on it.